LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 41 of 66
Next
>>
>
1001 to 1025 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Palbociclib	180619_MC_10	1431	0.0626	70	24	6	15	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_2	94	0.0616	635.9	71.1	15071	356.7	0.0231	0.03857	0.1944
Palbociclib	180619_MC_10	1699	0.0707	82	44	11	4	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_3	126	0.0690	635.9	71.1	15071	356.7	0.0231	0.04597	0.2401
Palbociclib	180619_MC_11	2443	0.0367	61	31	6	18	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_4	92	0.0363	635.9	71.1	15071	356.7	0.0231	0.01322	0.3428
Palbociclib	180619_MC_11	2522	0.0426	84	27	10	16	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_5	111	0.0422	635.9	71.1	15071	356.7	0.0231	0.01908	0.3521
Palbociclib	180619_MC_11	2625	0.0396	76	31	11	18	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_6	107	0.0392	635.9	71.1	15071	356.7	0.0231	0.01609	0.3641
Palbociclib	180619_MC_12	2744	0.0546	115	41	4	13	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_7	156	0.0538	635.9	71.1	15071	356.7	0.0231	0.03072	0.3774
Palbociclib	180619_MC_12	2558	0.0648	127	47	9	18	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_8	174	0.0637	635.9	71.1	15071	356.7	0.0231	0.04062	0.3563
Palbociclib	180619_MC_12	3266	0.0452	117	36	11	20	Palbociclib	3.160329361	treatment	72	2	MCF10A-GM_9	153	0.0447	635.9	71.1	15071	356.7	0.0231	0.02168	0.4309
Trametinib	180619_MC_10	12370	0.0195	69	173	9	20	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_1	242	0.0192	635.9	71.1	15071	356.7	0.0231	-0.00389	0.9153
Trametinib	180619_MC_10	12512	0.0174	61	158	10	4	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_2	219	0.0172	635.9	71.1	15071	356.7	0.0231	-0.00587	0.9201
Trametinib	180619_MC_10	12386	0.0201	53	197	11	11	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_3	250	0.0198	635.9	71.1	15071	356.7	0.0231	-0.00329	0.9159
Trametinib	180619_MC_11	11901	0.0256	102	205	3	19	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_4	307	0.0251	635.9	71.1	15071	356.7	0.0231	0.00207	0.8992
Trametinib	180619_MC_11	11738	0.0217	55	201	4	17	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_5	256	0.0213	635.9	71.1	15071	356.7	0.0231	-0.00173	0.8935
Trametinib	180619_MC_11	11326	0.0198	64	161	14	19	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_6	225	0.0195	635.9	71.1	15071	356.7	0.0231	-0.00360	0.8787
Trametinib	180619_MC_12	13429	0.0257	109	239	5	16	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_7	348	0.0253	635.9	71.1	15071	356.7	0.0231	0.00219	0.9501
Trametinib	180619_MC_12	12881	0.0333	138	296	7	11	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_8	434	0.0326	635.9	71.1	15071	356.7	0.0231	0.00952	0.9324
Trametinib	180619_MC_12	14160	0.0200	75	209	12	19	Trametinib	0.000332667	treatment	72	2	MCF10A-GM_9	284	0.0197	635.9	71.1	15071	356.7	0.0231	-0.00341	0.9729
Trametinib	180619_MC_10	9272	0.0145	29	106	6	8	Trametinib	0.000998	treatment	72	2	MCF10A-GM_1	135	0.0144	635.9	71.1	15071	356.7	0.0231	-0.00872	0.7982
Trametinib	180619_MC_10	7574	0.0168	54	74	10	19	Trametinib	0.000998	treatment	72	2	MCF10A-GM_2	128	0.0166	635.9	71.1	15071	356.7	0.0231	-0.00646	0.7203
Trametinib	180619_MC_10	7318	0.0201	52	96	14	21	Trametinib	0.000998	treatment	72	2	MCF10A-GM_3	148	0.0198	635.9	71.1	15071	356.7	0.0231	-0.00325	0.7074
Trametinib	180619_MC_11	8259	0.0290	54	187	5	5	Trametinib	0.000998	treatment	72	2	MCF10A-GM_4	241	0.0284	635.9	71.1	15071	356.7	0.0231	0.00528	0.7532
Trametinib	180619_MC_11	8941	0.0291	90	173	7	15	Trametinib	0.000998	treatment	72	2	MCF10A-GM_5	263	0.0286	635.9	71.1	15071	356.7	0.0231	0.00550	0.7839
Trametinib	180619_MC_11	7945	0.0339	88	184	7	21	Trametinib	0.000998	treatment	72	2	MCF10A-GM_6	272	0.0331	635.9	71.1	15071	356.7	0.0231	0.01003	0.7384
Trametinib	180619_MC_12	8947	0.0290	93	169	4	18	Trametinib	0.000998	treatment	72	2	MCF10A-GM_7	262	0.0285	635.9	71.1	15071	356.7	0.0231	0.00538	0.7842
Trametinib	180619_MC_12	9131	0.0246	131	97	9	19	Trametinib	0.000998	treatment	72	2	MCF10A-GM_8	228	0.0244	635.9	71.1	15071	356.7	0.0231	0.00129	0.7922

|<
<<
Previous
Page 41 of 66
Next
>>
>
1001 to 1025 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)